Supernus Pharmaceuticals Inc.

Supernus develops and sells FDA‑approved CNS therapeutics such as Qelbree (ADHD) and GOCOVRI (PD), plus high‑potential pipeline candidates in epilepsy, depression, and Parkinson’s, positioning it for growth in neurological markets.

Headquarters: United States (USA)

Supernus Pharmaceuticals Inc. Logo
Company Profile
  • Employees: 674
  • HQ: Rockville
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
SUPN Supernus Pharmaceuticals Inc.
Cap: 2.9B
EQUITY NGM USD US8684591089 Active
📈
Home Login